IP Library › Granted Patent US 12,195,769
Granted Patent B2
US 12,195,769 · App. 17/253,266 · Granted Jan 14, 2025

Lipolytic enzyme variants

Inventors: Joke Anneleen Putseys (Echt, NL); Neil Carr (Echt, NL); René Marcel De Jong (Echt, NL); Aloysius Wilhelmus Rudolphus Hubertus Teunissen (Echt, NL)
Assignee: DSM IP ASSETS B.V.
C12N9/20A21D6/00A21D8/042C12Y301/01003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,769
App. No.
17/253,266
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention relates to a variant polypeptide having a lipase activity, wherein the polypeptide may be a polypeptide that has an amino acid sequence which has at least 70% identity to a mature amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6, wherein the polypeptide comprises an amino acid substitution at position 295 and at least one further amino acid substitution at position 113, 121, 179 and/or 284, wherein the positions are defined with reference to SEQ ID NO: 1 or SEQ ID NO: 6. The invention further relates to a process for preparing a dough wherein a polypeptide as disclosed herein is used and baked product prepared from the dough.

Claims (27)

1. A variant polypeptide having a lipase activity, wherein the polypeptide is selected from the group consisting of:

i. a polypeptide which comprises an amino acid sequence which has at least 90% identity to a mature amino acid sequence comprising amino acids 34 to 304 of SEQ ID NO: 1, wherein the polypeptide comprises an amino acid substitution at position 295 and at least one further amino acid substitution at position 113, 121, 179 and/or 284, wherein the positions are defined with reference to SEQ ID NO: 1;

ii. the polypeptide according to i), wherein the amino acid substitution at position 295 is D295G, D295N or D295S and the at least one further amino acid substitution at position 113 is I113H, I113N or I113T, at position 121 the amino acid substitution is N121D, at position 179 the amino acid substitution is V179M, and/or at position 284 the amino acid substitution is I284M or I284T;

iii. a polypeptide which has at least 90% identity to a mature amino acid sequence comprising amino acids 34 to 304 of SEQ ID NO: 1, wherein the polypeptide comprises amino acid substitutions (D295S and V179M), (D295N and V179M), (D295S, I113H and V179M), (D295G and I113T), (D295N and I113N), (D295N, I113T, V179M, and N112D), (D295S, I113H, V179M, and I284M), (D295N and I113T), (D295S, I113T, V179M, and I284M), (D295S, I113T, V179M, N121D), (D295S, I113T and V179M), (D295S and I113N), or (D295N and I284T), wherein the substitutions are defined with reference to SEQ ID NO: 1;

iv. the polypeptide according to i)-iii), wherein the polypeptide comprises an insertion of one or more amino acid(s) after position 304, wherein the position is defined with reference to SEQ ID NO: 1; and

v. the polypeptide according to iv), wherein the mature amino acid sequence of SEQ ID NO: 1 comprises the insertion.

2. The polypeptide according to claim 1 , wherein the insertion comprises a proline at position 305 and 306.

3. The variant polypeptide according to claim 1 , wherein the polypeptide, when used in dough, improves shock resistance of dough, dough stability and/or increases the volume of a baked product made from the dough as compared to the shock resistance, dough stability and/or volume of a baked product made from a dough comprising a reference polypeptide, wherein said reference polypeptide is the mature amino acid sequence of SEQ ID NO: 1.

4. A nucleic acid encoding a polypeptide having lipase activity according to claim 1 , wherein optionally the nucleic acid has at least 70% 90% identity to SEQ ID NO: 2 or SEQ ID NO: 4, wherein the nucleic acid comprises a mutation encoding an amino acid substitution D295G, D295N or D295S and at least one further amino acid substitution I113H, I113N or I113T, and/or N121D, and/or V179M, and/or I284M or I284T, wherein the substitutions are defined with reference to SEQ ID NO: 1.

5. An expression vector comprising a nucleic acid according to claim 4 operably linked to at least one control sequence that direct expression of the polypeptide in a host cell.

6. A recombinant host cell comprising a nucleic acid according to claim 4 , or an expression vector comprising said nucleic acid.

7. A method for preparation of a polypeptide according to claim 1 , comprising cultivating a host cell in a suitable fermentation medium, under conditions that allow expression of the polypeptide, and optionally recovering the polypeptide.

8. A composition comprising a polypeptide according to claim 1 .

9. A process for preparing a dough comprising adding a polypeptide according to claim 1 to the dough.

10. A dough comprising a variant polypeptide according to claim 1 .

11. A process for preparing a baked product comprising baking a dough according to claim 10 .

12. A product comprising a variant polypeptide according to claim 1 to increase shock resistance, improve stability of a dough and/or increase the volume of bread.

13. A process for increasing volume of a baked product, comprising

preparing a dough comprising a polypeptide according to claim 1 ,

subjecting the dough to a shock treatment, and

baking the dough,

wherein the volume of the baked product is increased as compared to the volume of a baked product prepared from a dough comprising a reference polypeptide, wherein said reference polypeptide is the mature amino acid sequence of SEQ ID NO: 1.

14. The process according to claim 13 , wherein the dough and/or the baked product comprises wholemeal flour and/or a flour comprising a free fatty acid content of between 0.01 to 0.8 w/w %.

15. The variant polypeptide according to claim 1 , wherein the polypeptide of i) and iii) comprises an amino acid sequence which has at least 95% identity to a mature amino acid sequence comprising amino acids 34 to 304 of SEQ ID NO: 1.

16. The variant polypeptide according to claim 1 , wherein the polypeptide of i) and iii) comprises an amino acid sequence which has at least 97% identity to a mature amino acid sequence comprising amino acids 34 to 304 of SEQ ID NO: 1.

17. The variant polypeptide according to claim 1 , wherein the polypeptide of i) and iii) comprises an amino acid sequence which has at least 99% identity to a mature amino acid sequence comprising amino acids 34 to 304 of SEQ ID NO: 1.

18. The variant polypeptide according to claim 1 , wherein the polypeptide of i) and iii) comprises an amino acid sequence which has 100% identity to a mature amino acid sequence comprising amino acids 34 to 304 of SEQ ID NO: 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: PUTSEYS, JOKE ANNELEEN; CARR, NEIL; DE JONG, RENÉ MARCEL; TEUNISSEN, ALOYSIUS WILHELMUS RUDOLPHUS HUBERTUS
To: DSM IP ASSETS B.V.
Reel/Frame 054683/0157 →
Priority Claims (1)
EP 18178445 · Jun 19, 2018 · regional
Continuity (1)
Related Publication 20210115418A1 · Apr 22, 2021
References Cited (45)
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 9101585B2 · Fritsche et al. · 2015 [cited by applicant]
US 9717774B2 · Fritsche et al. · 2017 [cited by applicant]
US 9895415B2 · Fritsche et al. · 2018 [cited by applicant]
US 9993523B2 · Fritsche et al. · 2018 [cited by applicant]
US 10064913B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10357540B2 · Fritsche et al. · 2019 [cited by applicant]
US 10420816B1 · Fritsche et al. · 2019 [cited by applicant]
US 20020197266A1 · Debinski · 2002 [cited by applicant]
US 20030228446A1 · Pearce · 2003 [cited by applicant]
US 20060228446A1 · Borch et al. · 2006 [cited by applicant]
US 20110229504A1 · Fritsche et al. · 2011 [cited by applicant]
US 20110262591A1 · Van Der Laan et al. · 2011 [cited by applicant]
US 20120058222A1 · Sorensen et al. · 2012 [cited by applicant]
US 20130045191A1 · Weinschenk et al. · 2013 [cited by applicant]
US 20140147552A1 · Van Der Laan et al. · 2014 [cited by applicant]
US 20150147347A1 · Fritsche et al. · 2015 [cited by applicant]
US 20170204372A1 · Mohler et al. · 2017 [cited by applicant]
US 20170304399A1 · Fritsche et al. · 2017 [cited by applicant]
US 20170312336A1 · Fritsche et al. · 2017 [cited by applicant]
US 20180000896A1 · Fritsche et al. · 2018 [cited by applicant]
US 20180051080A1 · Leonie et al. · 2018 [cited by applicant]
US 20180125929A1 · Fritsche et al. · 2018 [cited by applicant]
US 20180319884A1 · Leonie et al. · 2018 [cited by applicant]
US 20190290727A1 · Fritsche et al. · 2019 [cited by applicant]
DE 102016115246B3 · 2017 [cited by applicant]
WO 1998026057A1 · 1998 [cited by applicant]
WO 2009106575A1 · 2009 [cited by applicant]
WO 2011113819A2 · 2011 [cited by applicant]
WO 2016011210A2 · 2016 [cited by applicant]
WO 2016156202A1 · 2016 [cited by applicant]
WO 2018033291A1 · 2018 [cited by applicant]
WO 2018114912A1 · 2018 [cited by applicant]
International Search Report issued in counterpart application No. PCT/EP2018/080176, mailed Jan. 17, 2019. [cited by applicant]
Hickman et al., “Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies” Journal of Biomolecular Screening. (2016) vol. 21(8) 769-785. [cited by applicant]
German Search Report of German Patent Application No. 102017125888.4 dated Oct. 12, 2018. [cited by applicant]
Smith, M. J. et al., “Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification,” British Journal of Cancer BJC, vol. 100, pp. 1452-1464, 2009. [cited by applicant]
Tilman, Gaëlle et al., “Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells,” Molecular Cancer, vol. 6, pp. 1-13, 2007. [cited by applicant]
Qiao, Jie, et al., “Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics,” OncoTarget, vol. 6, pp. 29929-29946, 2015. [cited by applicant]
Köhler, G., et al., “Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion,” European Journal of Immunology, vol. 7, pp. 511-519, 1976. [cited by applicant]
Haskard, D.O., et al., “The Production of Human Monoclonal Autoantibodies from Patients with Rheumatoid Arthritis by the EBV—Hybridoma Technique,” Journal of Immunological Methods, vol. 74, pp. 361-367, 1984. [cited by applicant]
Huse, William D., et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Science, vol. 246, pp. 1275-1281, 1989. [cited by applicant]
International Search Report for Application No. PCT/EP2019/065992 mailed Aug. 6, 2019. [cited by applicant]
S. P. C. Tait and T. Galliard, “Effect on baking quality of changes in lipid composition during wholemeal storage,” Journal of Cereal Science, (1988), vol. 8, No. 2 : 125-137. [cited by applicant]
T. A. Clayton and W. R. Morrison, “Changes in Flour Lipids During the Storage of Wheat Flour,” Journal of Science of Food & Agriculture, (1972), vol. 23, 721-735. [cited by applicant]